News >

Revised Guidelines Helping to Advance Kidney Cancer Care

Gina Columbus @ginacolumbusonc
Published: Friday, Oct 13, 2017

Robert G. Uzzo, MD

Robert G. Uzzo, MD
Management of patients with localized kidney cancer became a more uniformed, guided, and evidence-based approach earlier this year with revised guidelines individually developed by the American Society of Clinical Oncology (ASCO), American Urological Association (AUA), and the American College of Radiology (ACR).

on Renal Cell Carcinoma and Bladder Cancer. In an interview at the event, he honed in on recent guidelines that have impacted clinical practice and ongoing biomarker research in the field.

OncLive: What did you discuss in your lecture regarding localized kidney cancer?

Uzzo: The management of localized kidney cancer is increasingly complicated. Over the course of the last couple of years, we have developed more guidelines. It is not just a matter of when the surgery ought to be or how it’s going to be performed if surgery is indicated. We spoke about excision, ablation, and observation as the most common paradigm for [how] you should treat kidney cancer. What I spoke about is what ASCO, AUA, and ACR say about that. I should disclose that I was part of all 3 of those guidelines. 

What are the specifics of those guidelines? 

There is an increased emphasis on biopsy to determine and risk stratify prior to any plans for excision, ablation or even observation. The use of percutaneous biopsy, particularly core biopsy as a risk-stratifying tool, is an important aspect. Many physicians believe that biopsy is associated with a risk of tumor spillage which, fortunately, is not the case. It is more anecdotal and older data. Biopsy does not seem to be associated with a higher risk of tumor dissemination or seeding. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication